Lactose Intolerance Clinical Trial
Official title:
The Effect of Probiotics on Lactose Intolerance
Lactose intolerance (LI), also known as lactose malabsorption is the most common type of
carbohydrate malabsorption. It is associated with the inability to digest lactose into its
constituents, glucose and galactose, due to low levels of lactase enzyme activity (1-2). At
birth, lactase activity is at the highest and it declines after weaning (1-2). The
unabsorbed lactose is metabolized by colonic bacteria to produce gas (hydrogen (H2) and
methane (CH4)) and short chain fatty acids. Symptoms related to LI appear 30 minutes to 2
hours after consumption of food products containing lactose. Related symptoms include:
bloating, cramping, flatulence and loose stool (1-2, 17-18).
Highest rates of LI are found in the Asian populations, Native Americans and African
Americans (60-100%), while lowest rates are found in people of northern European origin
(including northern Americans) (3-4).
The diagnosis of LI based on patients' symptoms is sometimes problematic, since these
symptoms are not specific and may differ from one patient to another. Breath hydrogen test
have been advocated as the best diagnostic tool for the assessment of LI (15-16). During the
test, subjects are sampled for hydrogen levels of breath samples at base line and every 30
minutes after the administration of 50 grams of oral lactose, for a total period of 180
minutes. A breath sample with > 20 ppm above baseline is considered positive for LI (15-16).
There are no established treatments for LI, other than almost complete avoidance of lactose
rich dairy products. Avoidance of dairy products is a major concern since its outcome may
result in a dietary calcium intake that is well below recommended dose of 1,000 mg per day
for men and women and 1,300 mg for adolescents (8-10). For this reason different course of
action needs to be considered instead of a complete exclusion of dairy products by LI
patients.
Two possible interventions in the case of LI are the supplement of commercially available
lactase (tablets) or the addition of probiotics.
The consumption of lactase enzyme as a food supplement may assist in restoring adequate
levels of the enzyme needed for hydrolysis of lactose, especially for patients with low, or
non existent levels of lactase. On the other hand, lactase products are problematic since
not all lactase preparations are of the same concentration. Moreover, it is difficult to
asses the amount of lactase tablets needed in order do fully hydrolyze lactose in each dairy
mill (14).
Probiotics are live microorganisms that are commonly used in order to prevent or treat a
disease. The current definition by the Food and Drug Administration and the World Health
Organization is "Live microorganisms which, when administered in adequate amounts, confer a
health benefit on the host." These microorganisms are a heterogeneous group, they are
nonpathogenic and produce beta- galactosidase or lactase intracellularly that may assist in
the digestion of lactose (11).
Studies have shown that people with lactose intolerance tolerated the lactose in yogurt
better than the same amount of lactose in milk. The assumption was that the presence of
lactase producing bacteria in the yogurt, especially Lactobacillus acidophilus, contributed
to the digestion and absorption of lactose (5-6, 13).
It was also found that the presence of Lactobacillus bulgaricus and Streptococcus
thermophilus alleviate lactose intolerance through their ability to produce lactase enzyme
(7).
Finally, in another study it was found that consumption of milk containing Bifidobacterium
longum resulted in significantly less hydrogen production and flatulence as compared to the
consumption of control pasteurized milk (12).
Based on the mentioned data, the investigators speculate that the administration of
probiotics may assist with the consumption of dairy products containing lactose. Therefore,
the aim of this study is to evaluate the effect of probiotics on patients with LI.
lactose hydrogen breath test (LHBT) will be performed at base line and at each visit (total
of 7 breath samples from each patient). All subjects will be presented for the lactose
hydrogen breath test after 8 hours fast.
At the initial stage, the subjects will take a base reading at time 0.
Subjects will then receive 50 g of lactose dissolved in a 100 ml of plain water and will
perform further breath test samples every 30 minutes for 3 h. All breath samples will be
end-expiratory and analyzed immediately by a Portable Breath Hydrogen Monitor (Gastro+
gastrolyzer, Bedfont Instruments, Holywell Lane, Upchurch, Kent, England). The concentration
of breath hydrogen will be measured in parts per million (ppm). The measurements will then
be plotted graphically and analyzed. The effect of probiotics on LI treatment will be
measured by the following criteria:
1. If hydrogen levels measured after 6 months of treatment will be lower than levels
measured at time 0 and/or patients will report a decrease of symptoms, the treatment of
LI with Probiotics will be considered successful.
2. If hydrogen levels measured after 6 months of treatment will be the same or higher than
levels measured at time 0 and/or patients will report an unchanged state or an increase
of symptoms, the treatment of LI with probiotics will be considered unsuccessful.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Completed |
NCT02518295 -
β-galactosidase Producing Probiotic Strains to Improve Lactose Digestion
|
N/A | |
Completed |
NCT00599859 -
Effects of Lactose on Fecal Microflora
|
N/A | |
Completed |
NCT02636413 -
Evaluation of LacTEST for the Diagnosis of Hypolactasia in Adults and Elderly Patients Presenting With Clinical Symptoms of Lactose Intolerance
|
Phase 4 | |
Completed |
NCT02406469 -
Effects Comparison of A1 and A2 Milk on Gastrointestinal Physiology, Symptoms and Cognitive Behavior
|
Phase 4 | |
Terminated |
NCT00247806 -
Prevalence of Lactose Intolerance Following Stem Cell Transplantation
|
Phase 1 | |
Completed |
NCT03814668 -
Effect of Probiotic Supplementation on Lactose Maldigestion Induced by Lactose Solution
|
N/A | |
Completed |
NCT03860051 -
Association Between Lactase Deficiency, and the Small Intestinal Microbiome in Adults.
|
||
Not yet recruiting |
NCT06107088 -
Effect of a Combination of Lactase and L. Salivarius DSM 34078 in Individuals With Lactose Intolerance
|
N/A | |
Completed |
NCT02703987 -
HYBRID: Hydrogen Breath Test in Lactose Digestion
|
N/A | |
Completed |
NCT00395954 -
Amount of Lactose Causing Symptoms in Lactose Intolerant People
|
Phase 0 | |
Completed |
NCT04164394 -
Effect of I31 Probiotic on Lactose Intolerance
|
N/A | |
Recruiting |
NCT05668468 -
A Bifido Bacteria to Improve Lactose Digestion and Tolerance
|
N/A | |
Completed |
NCT03563846 -
Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects
|
Phase 1 | |
Recruiting |
NCT02085889 -
Fructose and Lactose Intolerance and Malabsorption in Functional Gastrointestinal Disorders
|
||
Completed |
NCT03597516 -
Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
|
Phase 3 | |
Not yet recruiting |
NCT03563859 -
Evaluation of Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
|
Phase 3 | |
Completed |
NCT02171403 -
Comparison of the Colonic Metabolism in Patients With Lactose Intolerance and Healthy Controls
|
N/A | |
Completed |
NCT01145586 -
A Non-inferiority, Multicenter and Randomized, Multiple-Dose Study About a Treatment to Hypolactasia
|
Phase 3 | |
Completed |
NCT02902016 -
Modulation of Lactase Expression by a New PPARgamma Ligand in Duodenal Biopsies
|
N/A |